» Articles » PMID: 34421369

Liver Disease Symptoms Are Associated with Higher Risk of Adverse Clinical Outcomes: A Longitudinal Study of North American Adults with Chronic Hepatitis B

Overview
Journal GastroHep
Publisher Wiley
Specialty Gastroenterology
Date 2021 Aug 23
PMID 34421369
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Symptoms of chronic hepatitis B (CHB) are not well characterized.

Aims: To evaluate CHB symptoms and associations with disease activity and clinical outcomes.

Methods: Longitudinal data from 1,576 participants in the Hepatitis B Research Network Cohort Study who completed symptom assessments were analyzed. A composite symptom score was calculated using a Symptom Checklist (0=none to 40=extreme). Multivariable mixed models assessed variables associated with symptom change over time. Latent class symptom trajectories were evaluated. The cumulative probability of long-term clinical outcomes (new onset cirrhosis, hepatic decompensation, hepatocellular carcinoma, liver transplantation, death) was examined by baseline symptom groups.

Results: Participants median age was 42 (range:18-80), 51% were male, 75% Asian, (68% of whom were born outside North America) with a median follow-up of 4.2 years. On average, symptoms did not significantly change over time. The multivariable model identified several variables associated with higher symptoms during follow-up: being female, non-Asian, born in the US/Canada, lower education, higher AST, lower platelets, and more comorbidities. Two patient subgroups were identified based on longitudinal symptom trajectories: a low symptom group (92%, n=1,451) with symptom scores averaging 2.4 over time and a moderate symptom group (8%, n=125) with symptom scores averaging 11.5. During follow-up, 7.3% in the moderate symptom group, but only 3.2% of the low symptom group, developed adverse outcomes (p=0.02).

Conclusions: In this large cohort of CHB patients, symptoms were generally mild and stable over time. However, in some patients with moderate symptoms at baseline, deleterious clinical outcomes were more frequent in follow-up.

Citing Articles

Symptoms of Liver Disease During Tenofovir Therapy With or Without Peginterferon: Results from the Hepatitis B Research Network Immune Active Trial.

Evon D, Lin H, Khalili M, Wahed A, Yim C, Fontana R Dig Dis Sci. 2023; 68(12):4499-4510.

PMID: 37804353 PMC: 11149619. DOI: 10.1007/s10620-023-08108-8.

References
1.
Fried M . Side effects of therapy of hepatitis C and their management. Hepatology. 2002; 36(5 Suppl 1):S237-44. DOI: 10.1053/jhep.2002.36810. View

2.
Ruhl C, Everhart J . Upper limits of normal for alanine aminotransferase activity in the United States population. Hepatology. 2011; 55(2):447-54. PMC: 3268908. DOI: 10.1002/hep.24725. View

3.
Kowdley K, Wang C, Welch S, Roberts H, Brosgart C . Prevalence of chronic hepatitis B among foreign-born persons living in the United States by country of origin. Hepatology. 2011; 56(2):422-33. DOI: 10.1002/hep.24804. View

4.
Jang Y, Boo S, Yoo H . Hepatitis B Virus Infection: Fatigue-Associated Illness Experiences Among Koreans. Gastroenterol Nurs. 2018; 41(5):388-395. DOI: 10.1097/SGA.0000000000000335. View

5.
Mahadeva S, Mahfudz A, Vijayananthan A . Ethnicity influences pain after ultrasound-guided percutaneous liver biopsy. Eur J Gastroenterol Hepatol. 2015; 27(12):1378-81. DOI: 10.1097/MEG.0000000000000465. View